文献速递慢性静脉疾病

基于CHIVA策略的高强度聚焦超声治疗慢性静脉疾病

High-intensity-focused ultrasound treatment for the chronic venous disease based on the Cure Conservatrice et Hémodynamique de l'Insuffisance Veineuse en Ambulatoire (CHIVA) strategy.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2025-03-19

本回顾性研究纳入2020年3月至2024年2月接受SONOVEIN设备高强度聚焦超声(HIFU)治疗的183例患者共204条肢体,按CHIVA原则闭合反流点。24个月原发闭合率88.1%(95%CI 77.7%-98.4%),二次闭合率92.1%(95%CI 83.3%-100%),无重大并发症。作者认为HIFU是有效安全的非侵入性替代方法,需进一步研究评估长期疗效与安全性。

要点

  • HIFU按CHIVA原则闭合反流点,24个月原发累积闭合率88.1%(95%CI 77.7%-98.4%)。
  • 24个月二次累积闭合率92.1%(95%CI 83.3%-100%),无重大并发症。
  • 作者认为HIFU可作为慢性静脉疾病有效安全的非侵入性替代方法。

核心结论

  • HIFU在CHIVA原则下应用可获得高反流点闭合率,支持其作为慢性静脉疾病有效且安全的非侵入性替代方法。
  • 该技术可减少热消融相关风险(如皮肤烧伤和神经损伤),并弥补常规方法的局限。
  • 作者认为这些结果凸显HIFU作为静脉疾病管理颠覆性技术的潜力,并指出需进一步研究评估其长期疗效与安全性。

研究设计与样本

  • 回顾性研究,纳入2020年3月至2024年2月使用SONOVEIN设备治疗慢性静脉疾病的患者。
  • 纳入标准为有症状(CEAP ≥C2)且超声证实存在主干反流的患者。
  • 排除标准为年龄小于18岁、预期寿命小于12个月或孤立性静脉流出道梗阻的患者。
  • 治疗遵循CHIVA原则,针对反流点和近端静脉段进行闭合。
  • 主要终点为反流点闭合率和手术安全性;主要疗效定义为一次治疗即闭合静脉,次要疗效定义为需要更多次治疗。

主要发现

  • 共183例患者(131例女性,52例男性;平均年龄55.2岁)的204条肢体接受HIFU治疗。
  • 1周、1个月、6个月、12个月和24个月的原发反流点闭合率分别为85.1%、91.8%、93.7%、94.3%和95.5%。
  • 1周、1个月、6个月、12个月和24个月的二次闭合率分别为89.6%、95.4%、95.0%、95.4%和95.7%。
  • 24个月总体原发累积闭合率为88.1%(95%CI 77.7%-98.4%),二次累积闭合率为92.1%(95%CI 83.3%-100%)。
  • 未观察到重大并发症。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为HIFU在CHIVA原则下应用可作为慢性静脉疾病有效且安全的非侵入性替代方法。
  • 作者指出需进一步研究评估HIFU的长期疗效与安全性。

局限性

  • 原文报告为回顾性研究。
  • 原文在结论中自述需进一步研究评估HIFU的长期疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Chronic venous disease management has significantly advanced with minimally invasive techniques like endovenous thermal ablation. High-intensity focused ultrasound (HIFU) is a noninvasive alternative thermal ablation method enabling targeted vein closure without percutaneous access. This study evaluates the efficacy of HIFU treatment, combined with the Cure Conservatrice et Hémodynamique de l'Insuffisance Veineuse en Ambulatoire (CHIVA) strategy, in occluding leak points in patients with superficial venous reflux. METHODS: This retrospective study included patients treated for chronic venous disease using the SONOVEIN device from March 2020 to February 2024. Inclusion criteria were symptomatic patients (CEAP ≥C2) with ultrasound-confirmed truncal reflux. Patients under 18 years, with <12 months life expectancy, or isolated venous flow obstruction were excluded. Treatments followed CHIVA principles, targeting leak points and proximal vein segments for occlusion. Primary endpoints were leak point occlusion rates and procedural safety. In this study, primary efficacy was defined as vein closure with one treatment, whereas secondary efficacy was defined as the need for more. RESULTS: A total of 204 limbs in 183 patients (131 females, 52 males; mean age, 55.2 years) underwent HIFU treatment. Primary leak point occlusion rate at 1 week, and 1, 6, 12, and 24 months were 85.1 %, 91.8%, 93.7%, 94.3%, and 95.5%, respectively. Secondary closure rates at 1 week, and 1, 6, 12, and 24 months were 89.6 %, 95.4%, 95.0%, 95.4%, and 95.7%, respectively. Overall primary and secondary cumulative closure rates at 24 months were 88.1% (95% confidence interval, 77.7%-98.4%), and 92.1% (95% confidence interval, 83.3%-100%), respectively. No major complications were observed. CONCLUSIONS: HIFU achieves high leak point occlusion rates when applied under CHIVA principles, supporting its role as an effective and safe noninvasive alternative for chronic venous disease treatment. The technique minimizes risks associated with thermal ablation, such as skin burns and nerve damage, while addressing limitations of conventional methods. These results highlight the potential of HIFU as a disruptive technology in venous disease management. Further studies should assess its long-term efficacy and safety.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Izquierdo Lamoca LM, Reyero Postigo T, Morán Escalona S, et al. High-intensity-focused ultrasound treatment for the chronic venous disease based on the Cure Conservatrice et Hémodynamique de l'Insuffisance Veineuse en Ambulatoire (CHIVA) strategy. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 40118271. doi:10.1016/j.jvsv.2025.102233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。